Founders and Investors

Mabylon AG was spun out from ImmunoQure (www.immunoqure.com) in 2015. Mabylon uses ImmunoQure’s technology platform to clone antibodies from sero-positive samples. ImmunoQure AG is a significant shareholder of Mabylon. 

.